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Opinion statement
Primary central nervous system lymphoma is a particular challenge in clinical neuro-oncol-
ogy. In contrast to most other malignant brain tumors, it may be considered a curable dis-
ease at least in younger patients who can tolerate intensive treatment regimens. Yet,
therapeutic progress has been limited with little measurable improvement in outcome over
the last two decades, mainly due to the low incidence of this tumor, which impedes the
execution of large randomized clinical trials, and the failure of most large cooperative
groups to conduct such trials. Whenever possible, high-dose methotrexate (HD-MTX) is
the backbone of the therapeutic regimen. Response rates can be increased by the addition
of second agents like ifosfamide or cytarabine, however, their impact on overall survival is
less clear. Similarly, the use of the anti-CD20 antibody rituximab, commonly used in the
treatment of B cell lymphomas outside the CNS, remains controversial and has not been
examined in adequate clinical trials. The prognosis of patients, who do not qualify for
HD-MTX-based chemotherapy, is considerably poorer. Radiation therapy is an active treat-
ment with high response rates but does typically not result in long-lasting remissions. It
remains an important therapeutic option as a salvage therapy in patients progressing on or
no longer responding to HD-MTX-based treatment. The combination of HD-MTX and radi-
ation therapy does not prolong overall survival. It is associated with significant neurotox-
icity, and it should be avoided. Another matter of debate is whether consolidation therapy
by other means, such as high-dose chemotherapy followed by stem cell support, is themost
promising regimen. Given these numerous uncertainties, neuro-oncologists should strive
for a treatment of PCNSL patients within clinical trials to allow for the development of im-
proved therapeutic regimens.
Introduction
Primary central nervous system lymphoma (PCNSL) is
a rare extranodal form of Non-Hodgkin lymphoma
(NHL). Registry data from the United States report
that only 2.2 % of all intracranial tumors are lympho-
mas [1]. Immunodeficiency (e.g., congenital or ac-
quired such as human immunodeficiency virus [HIV]
infection) is associated with an increased risk for the
development of PCNSL. The improvement of antire-
troviral therapy resulted in a decreased incidence of
PCNSL in immunocompromised patients translating
into fewer young patients affected with PCNSL. This
contrasts with a continued increase in men and wom-
en aged 65 and older for reasons yet to be determined
[2]. In immunocompetent patients, the median age at
diagnosis is about 60 years.
PCNSL can involve all parts of the CNS including
supratentorial and infratentorial compartments, spinal
cord, meninges and cerebrospinal fluid (CSF). Finally,
intraocular manifestation, either alone, then referred
to as primary intraocular lymphoma (PIOL), or often
associated with CNS involvement, can occur. Patients
with PCNSL may present with various clinical symp-
toms and signs. The extent of personality changes, cog-
nitive disturbances and focal neurological deficits will
depend on tumor size, localization and extent of the
peritumoral edema. Intraocular involvement may
cause blurred vision or other complaints.
Computed tomography (CT) or preferentially mag-
netic resonance imaging (MRI) are used as imaging
techniques with single or multiple supratentorial ho-
mogeneous contrast-enhancing tumor masses as a typ-
ical finding [3]. There are no specific features, which
allow a reliable differentiation between PCNSL and
other primary or secondary brain tumors as well as in-
f l ammato ry l e s ions . The use o f u l t r a sma l l
superparamagnetic iron oxide (USPIO) nanoparticles
may improve the MRI diagnosis of PCNSL [4]. This
technique, however, has not yet entered the clinical
routine examination. Similarly, the value of positron
emission tomography (PET) imaging using different
tracers such as 18F-fluordeoxyglucose (18F-FDG) or
11C-methionine for the diagnosis and monitoring of
PCNSL has remained questionable [5–7]. Upon diag-
nosis of a lymphoma in the CNS, the diagnosis of
PCNSL can only be rendered after exclusion of tumor
manifestations outside the CNS. The detection of lym-
phoma cells in the CSF, also referred to as meningeal
dissemination, in the eye and cranial nerves is still
compatible with PCNSL. However, staging is recom-
mended in every patient to exclude other lymphoma
manifestations [8]. This is typically done by chest, ab-
domen and pelvis CT. Whether FDG-PET-based visual-
ization results in increased sensitivity remains unclear
[9]. Ocular infiltration must be ruled out by an appro-
priate ophthalmologic diagnostics. Vitrectomy follow-
ed by histopathological assessment of the aspirate is
used to definitely verify or exclude lymphoma mani-
festations in the eye [10]. Bone marrow diagnostics
may reveal the presence of tumors cells which, howev-
er, does not change the therapeutic approach in the
absence of other systemic lymphoma manifestations
[11]. Further recommendations of the International
Extranodal Lymphoma Study Group (IELSG) include
a lumbar puncture followed by CSF examination
and testicular ultrasound in older men to exclude
the presence of testicular lymphoma metastatic to
brain [8].
Histopathological assessment of PCNSL tissue re-
sults in the diagnosis of a diffuse large B cell lympho-
ma (DLBCL) in about 90 % of all patients. These
tumors typically express the B cell marker CD20, a pre-
requisite for consideration of treatment with the
monoclonal antibody rituximab (see below). Standard
cytology from body fluids such as vitreous or CSF may
be broadened using flow cytometry analysis as well as
PCR diagnostics of the rearranged immunoglobulin
heavy-chain genes. Histopathological features as well
as pitfalls in the diagnosis of PCNSL have been
reviewed elsewhere [12]. CNS lymphoma with a histo-
logical diagnosis other than DLBCL is rare, including
low-grade lymphomas and lymphomas of T cell origin
as very uncommon findings [13, 14].
Because of the variable course of the disease, sever-
al attempts have been made to group patients into dif-
ferent clinical prognostic groups, which may help to
estimate the clinical evolution. The “Memorial Sloan-
Kettering Cancer Center prognostic model” published
in 2006 is based on a large cohort of PCNSL patients
[15]. Patients younger than 50 years had by far the
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best outcome. In the group of patients aged 50 or
older, the performance status allowed for further sep-
aration between two groups with patients being
50 years or older and a Karnofsky performance status
(KPS) below 70 having the worst prognosis. A more
comprehensive prognostic score was proposed by the
IELSG using not only age and performance status
but also elevated lactate dehydrogenase (LDH) and
CSF protein levels as additional parameters which
are associated with poor outcome [16]. Furthermore,
the involvement of “deep brain structures” was deter-
mined as a negative factor and included in the prog-
nostic assessment. This allowed for a separation of
three patient groups, which differ in their prognosis.
Treatment
Similar to many other brain tumors, the available treatment modalities for
PCNSL comprise surgery, irradiation and chemotherapy, with a clear focus
on the latter two options. The agents or regimens (e.g., CHOP) commonly
used to treat systemic lymphoma have no or only marginal activity in PCNSL
[17]. There are probably several reasons including different biological
properties of the tumors cells and the presence of the blood-brain barrier that
impedes the penetration of many chemotherapeutics into the brain. Despite
some progress within the last years, many important questions regarding the
most effective treatment for PCNSL remain under debate. The rarity of
PCNSL precludes the rapid execution of well-designed clinical trials with
reasonable patient numbers and does not allow for rapid evaluation of dif-
ferent treatment regimens. Still, the publication of two larger randomized
trials within the last years has shown that such studies are feasible and
should be pursued within the next years [18, 19].
Surgery
The intention of surgery has been purely diagnostic for decades. However, an
unplanned subgroup analysis of the G-PCNSL-SG1 dataset, comprising several
hundred patients, revealed that complete resection may be associated with a
better outcome [20•]. These findings are in contrast to very small and older
retrospective series that suggested a biopsy-only approach. However, surgical
techniques have improved and intra-operative imaging including ultrasound
and MRI has advanced which might be the reason for this observation. Obvi-
ously, there will never be a randomized clinical trial comparing resection with
biopsy in patients with lesions suspicious for a cerebral lymphoma. Therefore,
based on the currently available evidence, complete resection should be con-
sidered in case of single lesions, which may be removed safely. In the case of
multiple lesions or localization of the tumor mass in an eloquent region of the
brain, open or stereotactic-guided biopsy will remain the gold standard because
of the overall low risk of complications of such a procedure.
Radiation therapy
Radiation therapy has been used for decades for the treatment of PCNSL, but
its role has been diminishing over the last years. Treatment of PCNSL has
traditionally been considered to require the whole brain as the target volume
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(WBRT). Standard WBRT doses are typically 40-50 Gray (Gy) with single
fractions of not more than 2 Gy. Administration of higher doses does not
result in prolonged disease control, but causes more neurotoxic side effects
[21]. Trials, which assessed radiotherapy compared with supportive care, did
not exist, but there is no doubt that WBRT is active against PCNSL. However,
although high response rates can be achieved, they are commonly short-
lasting. Furthermore, there has been increasing evidence that irradiation is
associated with considerable neurotoxicity, particularly in combination with
MTX-based chemotherapy and in elderly patients [22]. Major questions,
which have been addressed, but only partially resolved within the last years,
included the following:
– Is there any role for dose-reduced irradiation?
– Does consolidating radiation therapy after MTX-based chemothera-
py prolong progression-free (PFS) and overall survival (OS)?
– When irradiation is deferred in patients who achieve a complete remis-
sion (CR) by chemotherapy alone, is it still active as a salvage treatment?
Several analyses indicate that the addition of WBRT to HD-MTX is associated
with a considerable risk of cognitive impairment. In contrast, a profoundly lower
incidence of neurotoxic effects is observedwhenHD-MTXwas applied alone [23,
24••]. Because of these problems, the concept of dose-reduced WBRT was de-
veloped aiming at avoiding cognitive side effects, but still being active as con-
solidation. A report by Shaw and colleagues indicated a lack of neurocognitive
decline when patients received consolidating WBRT with 23.4 Gy in 1.8 Gy/
fraction after HD-MTX-based chemotherapy [25]. Owing to the lack of a control
group, a benefit of the consolidation treatment could not be determined.
However, because of the futility of (higher) standard dose WBRT to prolong OS
following MTX-based chemotherapy in the G-PCNSL-SG1 trial (see below), it
can be anticipated that RTwith a decreased dosewill not providemore benefit in
terms of survival unless an unusual dose response relationship of RT for PCNSL
was postulated. When RT is deferred, it is still active in the situation of tumor
recurrence. A retrospective case collection comprising 48 patients demonstrated
an overall response rate of 79 % and amedian OS of 16 months [26] suggesting
that WBRT is an active treatment for patients with recurrent or refractory PCNSL.
Chemotherapy
Chemotherapy is regarded the treatment of first choice for patients newly
diagnosed with PCNSL. Chemotherapy-only approaches can result in high
response rates and, even more important, long-lasting remissions. There is a
debate, however, on the most active compounds to be added to the
established backbone of high-dose (HD)-MTX chemotherapy. The lack of
benefit from many drugs which are used for the treatment of systemic lym-
phoma including the CHOP regimen is most likely due to their insufficient
penetration of the blood-brain barrier [27].
Methotrexate alone or in combination
MTX doses that are commonly administered are in the range of 3 to 8 g/m2,
typically infused over 3 hours in 2 week-intervals. Doses less than 3 g/m2 are
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probably too low to reach sufficient concentrations in the CSF to kill lymphoma
cells [28, 29]. A doseof 8 g/m2MTXwas frequently associatedwith the need for a
dose reduction during the course of the treatment, mostly due to renal toxicity
[30, 31]. Therefore,most investigators chose a dose ofMTX in the range of 3-4 g/
m2 for combined therapeutic approaches with additional drugs. Various com-
binations of MTX with other agents have been evaluated within the last three
decades. However, the design of these corresponding reports, commonly either
from retrospective case collections and limited size or both, and the data from
few uncontrolled, but at least prospective series does not allow for final con-
clusions and precludes definition of a standard of care beyond HD-MTX
(reviewed in [32]). In fact, there are only four randomized trials in PCNSL of
which one was closed early for poor patient accrual. Drugs, which have been
frequently used in combination with MTX, include cytarabine, ifosfamide,
temozolomide, procarbazine, vincristine and rituximab. Various regimens have
been assessed aiming at increasing response rates and duration of response. The
only randomized trial comparing MTX alone (3.5 g/m2) with MTX (3.5 g/m2)
plus high-dose cytarabine (four cycles of 2 g/m2) followed by WBRT as con-
solidation treatment in both arms demonstrated a superior response rate to the
chemotherapy part in the MTX/cytarabine arm (CRR=46 %) compared to only
18 % in the cohort of patients receiving MTX alone [19]. The disappointingly
and exceptionally poor results of the single agent MTX are likely because MTX
was administeredonly every 3weeks rather than the usual every 2weeks, leading
to a decreased and insufficient dose intensity. This is also reflected by the fact
that only 15 % of the patients in the MTX only arm experienced grade 3/4 he-
matological toxicity. There was also a trend towards prolonged survival with the
combination (3 year OS: 46 % vs. 32 %). An analysis of the G-PCNSL-SG1 trial
indicates that increased response rates do not necessarily translate into
prolonged OS. In this study, the addition of ifosfamide to HD-MTX re-
sulted in increased CR rates but no superiority in terms of OS compared
to HD-MTX alone was observed. In line with these findings, a compre-
hensive Cochrane database review concluded that the addition of other
drugs to MTX may result in increased response rates as well as prolonged
PFS whereas the benefit on OS remains unclear. In contrast, toxicity is
significantly higher with combined treatment regimens [33]. Therefore,
randomized trials with higher patient numbers and longer follow-up are
required todetermineultimately thebenefit frompolychemotherapy asopposed to
HD-MTX alone.
Chemotherapy and additional radiotherapy
Consolidating radiation therapy has been explored as an adjunct to che-
motherapy for at least 20 years. There are numerous uncontrolled phase II
studies exploring MTX-based regimens with additional WBRT resulting in
variable response rates and survival data. These trials cannot be compared to
each other because of their different designs [34–37]. However, it became
clear that the addition of WBRT to chemotherapy is associated with consid-
erable neurotoxicity, particularly in elderly patients. Only in 2010, the results
of the randomized G-PCNSL-SG1 trial, which enrolled more than 500 pa-
tients with newly diagnosed PCNSL, were published [18]. The addition of
WBRT to MTX-based chemotherapy resulted in prolonged PFS (18 months
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for the WBRT group versus 12 months for patient who did not receive WBRT)
whereas no difference in OS was observed (32 and 37 months, respectively).
The trial was criticized for the long time needed for patient accrual, the high
number of patients lost to follow-up and specifically the fact that approxi-
mately one in four patients did eventually not adhere to the randomization
result, an inherent problem if patients are randomized several months prior
to the time point where randomization becomes effective. However, the
per-protocol as well as the intention-to-treat analysis yielded similar results
for the major outcome measures, indicating that irradiation can be deferred until
relapse after MTX-based first-line therapy. WBRT retains its role as a valuable
treatmentoption inpatientswho fail to respond sufficiently to initial chemotherapy
or do not qualify for MTX-based treatment, but outcome in relapsed PCNSL is
commonly poor and long-term survival after WBRT would likely be long-term
survival with cognitive impairment.
Other approaches for consolidation therapy
Because of the failure of WBRT to prolong OS when used as a consolidation
treatment and the significant long-term toxicity associated with its adminis-
tration, other strategies aiming at avoiding immediate irradiation have been
evaluated. One of the most promising approaches is high-dose chemother-
apy (HDC) with subsequent autologous stem cell transplantation (ASCT),
while omitting WBRT. This concept that has emerged over the last 15 years
may be a promising strategy, in particular for younger and fit patients. HDC
followed by ASCT has been examined in relatively small and uncontrolled
trials both in patients with newly diagnosed as well as refractory and recur-
rent PCNSL. Various conditioning therapies have been used including a
combination of thiotepa together with busulfane or carmustine (BCNU) or
the BEAM regimen (carmustine, etoposide, cytarabine, melphalan). Several
smaller trials combined a HDC approach with additional irradiation yielding
excellent survival results that, however, might be again compromised by late
neurotoxicity [38–40]. Overall, MTX-based chemotherapy followed by high-
dose therapy with carmustine and thiotepa and subsequent ASCT with or
without WBRT resulted in promising long-term survival with a 5-year OS of
70 % [41]. Further studies reported promising results without significant
neurotoxicity when HDC and subsequent ASCT were administered without
additional WBRT [42–44].
Another approach assessed induction chemotherapy with MTX, temozo-
lomide and rituximab followed by consolidation with etoposide and high-
dose cytarabine for patients who achieved stable disease or better after in-
duction. The 2-year OS was 58 % when all patients were analyzed and 93 %
in the cohort of patients who had qualified for and received consolidation
therapy with etoposide and cytarabine without evidence of neurotoxicity
[45]. This regimen was further evaluated within a multicenter study resulting
in survival curves, which display evidence of a plateau. The median OS had
not yet been reached after a median follow-up of 4.9 years [46••]. These
results indicate that chemotherapy alone can result in excellent long-term
survival. However, the potential benefit of polychemotherapy and HDC/
ASCT compared to standard chemotherapy alone needs to be confirmed in
randomized trials.
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Other drugs
In contrast to the unquestioned importance of MTX as the backbone of
any first-line regimen, it is much less clear which other agents should be
used in case of tumor recurrence, absence of response or for patients
who cannot tolerate HD MTX. In the following section, we summarize
some of the drugs that are frequently used either alone or as part of
combined regimens.
Steroids
Similar to other brain tumors, the administration of corticosteroids results in
a reduction of the peritumoral edema [47]. However, steroids also have a
transient direct anti-tumor effect against lymphoma cells through induction
of apoptosis, which can result in a rapid decrease of the size of the tumor
mass. When steroids are administered before surgery, they may preclude
histological confirmation of the diagnosis.
Rituximab
The putative beneficial role of rituximab, a monoclonal antibody targeting
the cell surface antigen CD20, which is found in the majority of PCNSL,
remains a matter of debate. Being part of most therapeutic regimens against
systemic B cell lymphomas, its activity against lymphomas in the CNS is
doubtful. CSF levels of rituximab after systemic application are approxi-
mately 0.1 % of serum levels, a phenomenon which is mainly caused by the
presence of the blood-brain barrier which hampers the penetration of the
antibody into the CSF [48]. Still, monotherapy with rituximab in the setting
of recurrent PCNSL was reported to yield occasional radiographic responses
in up to 33 % of patients without major toxicity concerns [49]. This may
reflect the partially disrupted blood-brain barrier in PCNSL, which may still
allow the antibody reaching some of brain lymphoma cells. Series looking at
the efficacy of rituximab when added to a MTX-based regimen suggest a
certain activity in PCNSL which is associated with increased CR rates that
may eventually translate into prolonged OS without adding significant tox-
icity [50, 51]. However, these studies have limited value due to their retro-
spective nature. The results of the ongoing prospective HOVON 105
(EudraCT no. 2009-014722-42) and IELSG32 (NCT01011920) trials, which
explore the activity of rituximab in a randomized fashion need to be awaited.
Similarly, the role of intrathecal administration of rituximab has not yet been
determined (see below).
Temozolomide
Temozolomide crosses the blood-barrier and has been included in several
MTX-based regimens (see above). It has been mainly examined in patients
with recurrent PCNSL who had previously been treated with MTX. Here,
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single-agent temozolomide was typically well tolerated whereas its activity
was overall limited with CR rates in the range of 20-30 % [52, 53].
Temozolomide alone, when used as first-line therapy in elderly patients
who did not qualify for MTX-based chemotherapy, had also only modest
activity (see below). The efficacy of temozolomide may depend on the
activity of the DNA repair protein O6-methylguanine DNA methyltrans-
ferase (MGMT). In retrospective series, low MGMT protein expression
examined by immunohistochemistry or high MGMT promoter meth-
ylation determined by methylation-sensitive high resolution melting
(HS-HRM) analysis were predictive for response to temozolomide [54,
55]. However, larger series examining the predictive or prospective
value of the MGMT status in PCNSL are lacking.
Topotecan
Topotecan is a topoisomerase I inhibitor that has been administered to
patients with recurrent or MTX-refractory PCNSL. Treatment with
topotecan can induce considerable response rates but may be associated
with significant toxicity [56, 57].
Intrathecal therapy
Dissemination of lymphoma cells into the CSF is a common finding
although the reported incidence rates are varying most likely due to
different methods that were applied for the detection of meningeal af-
fection. The presence of lymphoma cells in the CSF is probably not a
negative prognostic marker [58]. Still, appropriate treatment of the CSF
may be a prerequisite for long-lasting remissions. MTX administered at
doses of 3 g/m2 or higher will adequately penetrate through the blood-
brain barrier to yield therapeutic CSF levels [59]. Therefore, intrathecal
therapy is not considered as a standard of care which is supported by
two retrospective analyses suggesting that additional intrathecal treat-
ment does not result in prolonged OS compared to patient cohorts that
were not treated intrathecally [60, 61]. In contrast, very promising results
of a trial using a polychemotherapy approach including intraventricular
therapy with MTX, prednisolone, and cytarabine were not reproduced
when the intrathecal treatment was omitted [62–64]. Intraventricular
administration of rituximab has been examined in a small cohort of
PCNSL patients. The drug was well tolerated but the beneficial effects
of this approach remain elusive [65]. Application of drugs by an
Ommaya reservoir or a similar device are frequently associated with
infectious complications and require an additional surgical procedure.
This may be circumvented by the repeated application of drugs by
lumbar puncture which, however, may not result in an equal distri-
bution of the compound in the CSF. Whether the addition of lumbar
or intraventricular treatment to MTX-based protocols results in
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prolonged OS needs further investigation and should be assessed
within appropriate clinical trials.
Elderly patients
Patients over age 60 are commonly referred to as “elderly”. However, some
studies focusing on elderly patients only include patients who are at least 65
or even 70 years old. Owing to this variability, it becomes difficult to com-
pare different studies enrolling elderly patients. As with younger patients,
MTX should be the backbone of any treatment concept in elderly patients
because of the lack of drugs with similar activity. In the elderly, HD-MTX is
commonly well tolerated and can be safely administered in most patients
[66]. Even in patients aged 80 and older, the application of MTX-containing
regimens was feasible and resulted in long-term survival in some patients
[67]. However, exceedingly high serum MTX levels, determined by area under
the curve (AUC) calculations, are associated with reduced survival and
should be avoided [68]. Promising CR rates can be achieved in elderly pa-
tients. However, the durability of these responses is reduced compared to
younger patients indicating that consolidation is required in elderly patients
in CR [66]. Again, various compounds have been added to MTX and assessed
in smaller trials. The combination of MTX with procarbazine and lomustine
resulted in a median OS of 15.4 months [69] which was only moderately
changed to 17.5 months when rituximab was added in a subsequent trial
[70]. A polychemotherapy regimen and additional intrathecal chemotherapy
yielded a median OS of 14.3 months in a study with 50 PCNSL patients who
had a median age of 72 years [71]. The combination of HD-MTX with
temozolomide was reported to be well tolerated and resulted in an OS of
25 months [72]. However, a randomized phase II study comparing two
different MTX-based regimens suggests higher activity of MPV-A (MTX, pro-
carbazine, vincristine and cytarabine) compared to MTX combined with
temozolomide [73•]. This trial, however, was not designed to prove
superiority and these results must be confirmed in a phase III trial. No
convincing treatment strategies are available for elderly patients who
cannot be treated with HD-MTX. Radiation therapy is active but has
several limitations as described above. Dose-intensified temozolomide
alone has only limited efficacy [74]. In summary, similar to younger
patients, HD-MTX should be used in the elderly whenever possible and
considered appropriate. The benefit of further agents that are added to
MTX remains to be determined.
Recurrent or refractory PCNSL
In the situation of recurrent or refractory PCNSL, no standard treatment has
been defined. Several options are available and the parameters, which should
be taken into account, include the performance status of the patient, benefit
from prior therapies and the interval between last treatment and tumor re-
currence. MTX re-challenge is generally considered promising in patients who
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achieved a CR upon MTX-based treatment [75]. In contrast, patients whose
tumors must be considered refractory to MTX should be offered an alterna-
tive treatment. Here, various approaches have been assessed. Similar to the
situation of newly diagnosed PCNSL, the quality of the available studies is
rather poor and randomized trials are lacking. WBRT is an active treat-
ment in the setting of recurrent PCNSL with high response rates, which,
however, frequently do not translate into long-lasting remissions [26,
76]. Temozolomide alone is well tolerated but has only modest activity
[53]. The combination of temozolomide and rituximab was examined
within a trial that was closed prematurely after a preliminary analysis
had suggested disappointing activity [77]. Novel approaches include the
administration of pemetrexed, a folate antimetabolite. In patients with
relapsed or refractory PCNSL, it had single-agent activity but was also
associated with considerable toxicity [78, 79]. Larger trials are required to
determine the value of pemetrexed in PCNSL in more detail. Finally,
HDC with subsequent ASCT may be a promising option for selected
patients with recurrent PCNSL who qualify for such an intense and
rather toxic approach [80, 81].
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